NCT01594515View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Healthy
Interventions
DRUG

BI 1015550

High dose powder for oral solution

DRUG

BI 1015550

Medium dose powder for oral solution

DRUG

BI 1015550

Low dose powder for oral solution

DRUG

BI 1015550

Low dose powder for oral solution

DRUG

BI 1015550

Low dose powder for oral solution

DRUG

Placebo

Solution for oral administration

DRUG

BI 101550

High dose powder for oral solution

DRUG

BI 1015550

Low dose powder for oral solution

DRUG

BI 1015550

Medium dose powder for oral solution

DRUG

BI 1015550

Medium dose powder for oral solution

Trial Locations (1)

Unknown

1305.1.1 Boehringer Ingelheim Investigational Site, Ingelheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY